Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17188885rdf:typepubmed:Citationlld:pubmed
pubmed-article:17188885lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0812413lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0007778lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0152463lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C2678502lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0278348lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C1883256lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0595451lld:lifeskim
pubmed-article:17188885lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:17188885pubmed:issue3lld:pubmed
pubmed-article:17188885pubmed:dateCreated2007-2-19lld:pubmed
pubmed-article:17188885pubmed:abstractTextFrom therapeutic nihilism to extremely aggressive management, there is a wide range of possibilities in the treatment of malignant pleural mesothelioma (MPM). Unfortunately, there is little evidence as regards the best treatment to offer to the MPM patients. In 1999, we started a phase II study based on the multimodality treatment of stage II-III MPM, the results of which have been analysed and reported.lld:pubmed
pubmed-article:17188885pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17188885pubmed:languageenglld:pubmed
pubmed-article:17188885pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17188885pubmed:citationSubsetIMlld:pubmed
pubmed-article:17188885pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17188885pubmed:statusMEDLINElld:pubmed
pubmed-article:17188885pubmed:monthMarlld:pubmed
pubmed-article:17188885pubmed:issn1010-7940lld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:ChellaAntonio...lld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:LucchiMarcoMlld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:MussiAlfredoAlld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:FontaniniGabr...lld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:DiniPaoloPlld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:AmbrogiMarcel...lld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:MelfiFrancaFlld:pubmed
pubmed-article:17188885pubmed:authorpubmed-author:FinoLeonardoLlld:pubmed
pubmed-article:17188885pubmed:issnTypePrintlld:pubmed
pubmed-article:17188885pubmed:volume31lld:pubmed
pubmed-article:17188885pubmed:ownerNLMlld:pubmed
pubmed-article:17188885pubmed:authorsCompleteYlld:pubmed
pubmed-article:17188885pubmed:pagination529-33; discussion 533-4lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:meshHeadingpubmed-meshheading:17188885...lld:pubmed
pubmed-article:17188885pubmed:year2007lld:pubmed
pubmed-article:17188885pubmed:articleTitleA phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.lld:pubmed
pubmed-article:17188885pubmed:affiliationDivision of Thoracic Surgery, Cardiac and Thoracic Department, University of Pisa, Pisa, Italy. m.lucchi@med.unipi.itlld:pubmed
pubmed-article:17188885pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17188885pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17188885lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17188885lld:pubmed